The Davion acquisition of Philadelphia-based Healthcare Stat Homecare is set to bring a home healthcare services business into the health technology company for $13.5 million. Davion Healthcare announced the agreement on October 29, 2026, and expects the transaction to close by year-end, subject to its terms.

Key Takeaways

  • The consideration comprises $8 million in cash and $5.5 million in Davion shares.
  • Healthcare Stat reported approximately $11.6 million in gross receipts for 2025, on an unaudited basis.
  • Davion said the deal is the first in a planned programme of healthcare acquisitions.

Davion acquisition terms and timing

The agreement, dated October 27, 2026, values the shares used as consideration at $13 each. Completion is expected on or before December 31, 2026, subject to the acquisition agreement’s terms. The transaction has not yet closed.

For the year ended December 31, 2025, Healthcare Stat reported approximately $1.9 million in ordinary business income alongside its $11.6 million in gross receipts. Both figures were unaudited.

What Healthcare Stat does

Healthcare Stat provides Philadelphia-area home healthcare services, including nursing, home health aide and rehabilitation care. Its staff includes nurses, aides, physical and occupational therapists, and social workers.

The business serves patients ranging from children to older adults. Its clinical programmes include wound care, dementia and diabetes care, telehealth and rehabilitation.

Davion’s expansion plans

Davion develops non-invasive health monitoring technologies. The proposed purchase would extend its activities into delivering care at home and, once completed, add an operating business with its own revenue and earnings.

The company said it plans further acquisitions of established, profitable healthcare businesses over the coming year. It also sees potential to evaluate its monitoring technologies in home healthcare, but said any integration or deployment plans would be developed after completion.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.